Sign up USA
Proactive Investors - Run By Investors For Investors

Mylan heads lower as it receives “tentative approval” for HIV/AIDS drug

The treatment combines three first-line therapies – Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate – into one smaller tablet that patients take three times a day
african man having blood sample taken at doctor's
There are currently around 37mln people living with HIV/AIDS around the world

Shares in Mylan Inc. (NASDAQ:MYL) dropped in pre-market trade on Monday after the pharma giant confirmed it has received “tentative approval” for its TLD HIV/AIDS antiretroviral (ARV) drug.

The treatment combines three first-line therapies – Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate – into one smaller tablet that patients take three times a day.

It’s the first fixed-dose combination of its kind to be offered to patients being treated for HIV/AIDS, Mylan said.

The US Food and Drug Administration gave its ‘tentative approval’ under the US President’s Emergency Plan for AIDS Relief – a governmental initiative designed to address the global HIV/AIDS epidemic, but with a particular focus on Africa.

“Our innovative TLD is a new medicine that will be available specifically to patients in the developing world being treated for HIV/AIDS,” said chairman Rajiv Malik.

“We know the challenges they face accessing high quality, affordable ARVs. That's why our scientists worked diligently to develop a medicine that combines three of the leading first-line regimens into a new, smaller tablet that patients have to take only once each day.”

Shares were down 4.5% in pre-market to US$31.35.

View full MYL profile View Profile

Mylan Inc. Timeline

Related Articles

picture of cannabis plants
March 23 2018
Control of the supply chain offers operational advantages and financial benefits.
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
researcher filling a vial
April 23 2018
2018 is shaping up to be a crucial year for the company's drug pipeline

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use